Jacob Chudnovsky

Jacob Chudnovsky has a diverse work experience in the field of translational oncology. Jacob currently holds the position of Director of Translational Sciences at Syndax Pharmaceuticals since 2022. Prior to this, they worked as the Director of Oncology Program at Sema4 from 2021 to 2022.

Before joining Sema4, Jacob worked at Foundation Medicine, where they held several roles. Jacob started as a Scientist II in Translational Oncology in 2014 and was later promoted to Senior Scientist I in 2016. In 2018, they became a Senior Scientist II and played a significant role in driving the implementation of tumor mutation burden (TMB) as a predictive biomarker for immunotherapy treatments.

Jacob'swork at Foundation Medicine also involved leading various initiatives, such as the development of microsatellite instability (MSI) as a companion diagnostic for an immune checkpoint inhibitor. Jacob was instrumental in obtaining FDA approval for the use of TMB as a companion diagnostic for pembrolizumab.

Prior to their tenure at Foundation Medicine, Jacob worked as a Postdoctoral Associate at the Whitehead Institute from 2006 to 2013. Jacob'sresearch focused on identifying genetic drivers of human glioblastoma tumor initiating cells (TICs) and they developed innovative image-based RNAi screens for this purpose.

Overall, Jacob Chudnovsky has a strong background in translational oncology and has made significant contributions to the development and implementation of predictive biomarkers in cancer treatment.

Jacob Chudnovsky obtained their doctoral degree in Cancer Biology from Stanford University School of Medicine between 2001 and 2006, under the guidance of Professor Paul A. Khavari. Prior to that, they completed their undergraduate studies at Harvard University, receiving a Bachelor of Arts degree in Biochemical Sciences from 1997 to 2001, with Professor J. Woodland Hastings as their mentor. Jacob also holds a High School Diploma from Seven Hills Upper School, although the specific years are not provided.